Research progress on the role of DDR1 in cancer and targeted therapy strategy
Abstract:
Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by various types of collagen. Abnormal activation of DDR1 is closely related to the occurrence and development of solid tumors and plays an important role in the regulation of cell adhesion, survival, proliferation, migration, and invasion. Thus, DDR1 is a promising therapeutic target in the field of oncology. This review introduces the structural characteristics of DDR1, focusing on its role in tumor progression and related signaling pathways. It also explores the relationship between DDR1 and tumor chemotherapy resistance, and elaborates on the current research status and development prospects for inhibitors and antibodies targeting DDR1. Thus, the DDR1 inhibition strategy may serve as a new alternative for treating cancer patients.
Received date: 10/10/2025
Accepted date: 02/06/2026
Ahead of print publish date: 02/19/2026
Keywords: DDR1, cancer progression, targeted therapy, selective inhibitors
DOI: doi:10.4149/neo_2026_251010N426